Actively Recruiting
Long-Term Follow-Up Study for Adults Aged 20 to 70 With Chronic Hepatitis B Previously Treated With Imdusiran
Led by Arbutus Biopharma Corporation · Updated on 2024-11-27
50
Participants Needed
18
Research Sites
8 weeks
Total Duration
AI-Summary
What this Trial Is About
The trial follows adults aged 20 to 70 with chronic hepatitis B CHB who previously received the investigational drug imdusiran and stopped nucleostide analog NA therapy during that earlier study. It aims to evaluate how long the effects of imdusiran on hepatitis B virus HBV parameters last over time. This observational study involves no new treatments and focuses on long-term monitoring. Participants enroll after completing their prior imdusiran trial and remain off NA therapy. The study involves no interventions beyond collecting blood samples, reviewing current medications, and recording any adverse events related to study procedures or if NA therapy is restarted. There are no additional study treatments. Participants will be followed for about 2 years to complete at least 3 years of follow-up since stopping NA therapy, including time in the parent study. Researchers will assess HBV markers to measure imdusirans lasting effect. Regular blood tests and medication reviews will monitor safety and disease status during the study.
CONDITIONS
Brief Title
Long-Term Follow-up Study for Subjects With CHB Previously Treated With Imdusiran (AB729)
Research Team
M
Michael Child
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
